Related Experiment Video

Updated: May 21, 2026

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

Sensor-augmented pump therapy in very young children with type 1 diabetes: an efficacy and feasibility observational

Giulio Frontino1, Riccardo Bonfanti, Andrea Scaramuzza

  • 1Department of Pediatrics, Endocrine Unit, Scientific Institute Hospital San Raffaele, Vita-Salute University, Milan, Italy. frontino.giulio@hsr.it

Diabetes Technology & Therapeutics
|June 15, 2012
PubMed

Insights

Sensor-augmented pump (SAP) therapy is effective for very young children with type 1 diabetes (T1D). This approach improved glycosylated hemoglobin (HbA1c) in those with high baseline levels, showing feasibility and good satisfaction.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Technology
  • Metabolic Disorders

Background:

  • Type 1 diabetes (T1D) management in very young children presents unique challenges.
  • Sensor-augmented pump (SAP) therapy combines continuous glucose monitoring with insulin pump technology.

Purpose of the Study:

  • To evaluate the efficacy and feasibility of SAP therapy in children younger than 7 years with T1D.
  • To assess the impact of SAP on glycemic control and patient satisfaction.

Main Methods:

  • Retrospective evaluation of 28 children (mean age 5.8 ± 1.2 years) with T1D using SAP therapy (Dexcom Seven Plus™ and insulin pump).
  • Assessment of glycosylated hemoglobin (HbA1c) at baseline and study end.
  • Evaluation of system efficacy and feasibility using a rating scale.

Main Results:

  • 85% of patients used SAP for ≥6 months with 92% overall satisfaction.
  • Reduced fear of hypoglycemia was the most significant perceived benefit (81%).
  • Significant HbA1c improvement observed in patients with baseline HbA1c >7.5% (P = 0.026).

Conclusions:

  • SAP therapy is effective and feasible for preschool-aged children with T1D.
  • SAP therapy led to a sustained 0.9% decrease in HbA1c in patients with high baseline levels.
  • The technology offers significant benefits, including reduced hypoglycemia concerns.
Abstract

More Related Videos

A Familiarization Protocol Facilitates the Participation of Children with ASD in Electrophysiological Research08:42

A Familiarization Protocol Facilitates the Participation of Children with ASD in Electrophysiological Research

Published on: July 31, 2017

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...